OppenheimerFunds Inc. raised its stake in shares of MEDNAX Inc (NYSE:MD) by 40.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 28,780 shares of the company’s stock after acquiring an additional 8,278 shares during the period. OppenheimerFunds Inc.’s holdings in MEDNAX were worth $1,538,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Fuller & Thaler Asset Management Inc. purchased a new position in shares of MEDNAX during the 3rd quarter worth approximately $103,000. Meiji Yasuda Asset Management Co Ltd. raised its stake in shares of MEDNAX by 45.3% during the 3rd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 5,230 shares of the company’s stock worth $226,000 after buying an additional 1,630 shares in the last quarter. Delta Capital Management LLC purchased a new position in shares of MEDNAX during the 4th quarter worth approximately $227,000. Brown Advisory Inc. purchased a new position in shares of MEDNAX during the 4th quarter worth approximately $231,000. Finally, YHB Investment Advisors Inc. purchased a new position in shares of MEDNAX during the 4th quarter worth approximately $235,000. 98.53% of the stock is owned by hedge funds and other institutional investors.
MD has been the subject of several research analyst reports. BMO Capital Markets raised their price objective on MEDNAX from $46.00 to $58.00 and gave the company a “market perform” rating in a research note on Monday, February 12th. JPMorgan Chase & Co. raised their price objective on MEDNAX from $46.00 to $55.00 and gave the company a “neutral” rating in a research note on Monday, February 12th. Mizuho reaffirmed a “neutral” rating and issued a $53.00 price objective (up from $49.00) on shares of MEDNAX in a research note on Friday, February 9th. Robert W. Baird raised their price objective on MEDNAX from $48.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, February 9th. Finally, Stephens set a $62.00 price objective on MEDNAX and gave the company a “buy” rating in a research note on Thursday, February 8th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $54.92.
MEDNAX (NYSE:MD) last announced its earnings results on Thursday, February 8th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.04. The firm had revenue of $910.82 million for the quarter, compared to analysts’ expectations of $884.55 million. MEDNAX had a return on equity of 10.10% and a net margin of 9.26%. MEDNAX’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.00 EPS. equities research analysts forecast that MEDNAX Inc will post 4.03 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “OppenheimerFunds Inc. Has $1.54 Million Holdings in MEDNAX Inc (MD)” was published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/03/14/oppenheimerfunds-inc-has-1-54-million-holdings-in-mednax-inc-md.html.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.